Anti-nucleolin Aptamer as a Boom in Rehabilitation of Breast Cancer

S K Janani1, S P Dhanabal2, Raman Sureshkumar1

  • 1Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

Insights

The AS1411 aptamer targets nucleolin on breast cancer cells, offering a novel approach for targeted delivery and potentially eradicating tumors through mechanisms like apoptosis and anti-angiogenesis.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Breast cancer is a leading cause of cancer mortality, necessitating advanced targeted delivery systems.
  • Targeted delivery systems utilize agents like aptamers to specifically interact with cancer cells.
  • Aptamers can be designed to target receptors overexpressed on cancer cell surfaces.

Purpose of the Study:

  • To discuss nucleolin as a target in breast cancer.
  • To explore the anti-cancer activities of the AS1411 aptamer against nucleolin.
  • To examine the internalization mechanisms and advantages of aptamers over antibodies.

Main Methods:

  • Review of literature on nucleolin, AS1411 aptamer, and breast cancer pathways.
  • Discussion of aptamer-mediated drug delivery and internalization processes (e.g., macropinocytosis).
  • Comparative analysis of aptamers versus antibodies for targeted cancer therapy.

Main Results:

  • AS1411 aptamer binds to overexpressed nucleolin in breast cancer cells.
  • Nucleolin's shuttling between nucleus and cytoplasm facilitates AS1411 internalization.
  • AS1411 exhibits anticancer activities including apoptosis, anti-angiogenesis, and anti-metastasis.

Conclusions:

  • AS1411 demonstrates significant potential in managing and eradicating breast cancer cells.
  • The aptamer's ability to stimulate tumor suppressors (P53) and inhibit tumor inducers is highlighted.
  • AS1411 offers advantages over antibodies, with discussed limitations.